ハルキ　シンタロウ   Haruki Shintarou   春木　伸太郎    所属   医学部 医学科（東京女子医科大学病院）    職種   助教
言語種別	英語
発表タイトル	Renal Function and the Prognostic Impact of Renin-angiotensin-aldosterone System Inhibitors for Heart Failure Patients: An Analysis of HIJ-HF II Study
会議名	The 83rd Annual Scientific Meeting of the Japanese Circulation Society (JCS2019)
主催者	Japanese Circulation Society
学会区分	全国規模の学会
発表形式	口頭
講演区分	一般
発表者・共同発表者	◎SUZUKI Keisuke, OYABU Kenjiro, SUZUKI Atsushi, MATSUI Yuko, NAGARA Kimiko, HARUKI Shintaro, KIKUCHI Noriko, HATTORI Hidetoshi, WATANABE Erisa, SUZUKI Tsuyoshi, SHIGA Tsuyoshi, HAGIWARA Nobuhisa
発表年月日	2019/03/29
開催地 （都市, 国名）	Yokohama, JAPAN
概要	*Featured Research Session 4 (HF/CM) Heart Failure, Cardiomyopathy (Clinical) Angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARB) reduce mortality and morbidity in patients with heart failure (HF). The aim of this study was to assess the impact of ACE-I or ARB on mortality among HF patients with and without renal dysfunction. After the exclusion of patients receiving regular hemodialysis, 536 HF patients discharged alive (age: 70±15 years, 34% female) from a multicenter hospital-based cohort consisted of HF patients between 2013 and 2014 were studied. Renal dysfunction was defined estimated glomerular filtration rate <60 mL/min/1.73 m2. During 17±10 months follow-up, there was a tendency that the mortality rate was higher in patients with renal dysfunction compared without renal dysfunction (18% vs. 13%). Although the mortality was significantly lower in ACE-I/ARB patients than nonACE-I/ARB patients among patients without renal dysfunction (Figure A), there was no difference in mortality between ACE-I/ARB and non-ACE-I/ARB patients among patients with renal dysfunction (Figure B). The effect of ACE-I/ARB on mortality might be difference in HF patients with and without renal dysfunction.